Given that fascin inhibitors do not induce apoptosis of bladder cancer cells, we investigated the combinatory therapy of NP-G2-044 and a chemotherapeutics agent, cisplatin, which is widely used for treating metastatic bladder cancers. Here, FSCN1 is linked to urinary bladder cancer.